-
Innovation Ranking
Innovation Ranking – GC Pharma
GC Biopharma Corp (GC Biopharma), formerly known as GC Pharma, a subsidiary of Green Cross Holdings Corp, provides plasma protein therapeutics and vaccines. The company develops, manufactures, and markets a wide product portfolio comprising plasma derivatives including albumin, immunoglobulin, and antithrombin; vaccines for infectious diseases; prescription drugs for treating cardiovascular, respiratory, central nervous system (CNS), gastrointestinal and immunology diseases, musculoskeletal disorders, genetic disorders, metabolic disorders and hematological disorders; and Over-the-counter (OTC) drugs including anti-inflammatory drugs, anti-allergic products, and others. The...
-
Product Insights
NewNet Present Value Model: Gracell Biotechnologies Inc’s GC-012F
Empower your strategies with our Net Present Value Model: Gracell Biotechnologies Inc's GC-012F report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-1118A in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-1118A in Gastric Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-1118A in Gastric Cancer Drug Details: GC-1118A is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-101 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-101 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-101 in Metastatic Melanoma Drug Details: GC-101 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-012F in Relapsed Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-012F in Relapsed Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-012F in Relapsed Multiple Myeloma Drug Details: GC0-12 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-012F in Refractory Multiple Myeloma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-012F in Refractory Multiple Myeloma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-012F in Refractory Multiple Myeloma Drug Details: GC0-12 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-3111A in Pertussis (Whooping Cough)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-3111A in Pertussis (Whooping Cough) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-3111A in Pertussis (Whooping Cough) Drug Details: GC-3111A is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GC-022 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GC-022 in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GC-022 in B-Cell Acute Lymphocytic Leukemia...
-
Sector Analysis
NewCAD/CAM Systems and Materials Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033
CAD/CAM Systems and Materials Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2033 is built to visualize quantitative market trends within Dental Devices therapeutic area. The model discusses in detail the impact of COVID-19 on CAD/CAM systems and materials market for the year 2020 and beyond. CAD/CAM systems are utilized in the processing and fabrication of dental prosthodontics. CAD/CAM systems improve in the design and fabrication of dental prostheses such as crowns, crown lays, veneers, inlays...
-
Thematic Analysis
NewTravel and Tourism M&A Deals Q1 2024 – Top Themes – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q1 2024 in the Travel & Tourism Sector